Status of adjuvant endocrine therapy for breast cancer.

This showed a trend toward improvement in overall survival (OS) for goserelin versus control (hazard ratio = 0.88, P = 0.14) and a greater benefit for combined goserelin plus tamoxifen versus goserelin (disease-free survival (DFS): hazard ratio = 0.74, P <0.01 and OS: hazard ratio = 0.91, P = 0.21), suggesting that there may be a benefit of adding tamoxifen to goserelin on DFS but not OS.

also in 53,322 other papers

Tamoxifen with chemotherapy There were highly significant recurrence reductions both in the six trials with no chemotherapy (RR = 0.56) and in the 14 trials of chemotherapy plus tamoxifen versus the same chemotherapy alone (RR = 0.67), and there was a slightly greater effect of tamoxifen in those with greater degrees of ER positivity in both trial categories [ 13 ].

also in 132,142 other papers

There was no significant difference in efficacy between OvA and OvS, despite a slight trend against the LHRH analogues.

also in 4,078 other papers